The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARDX | -12.38% | +4.29% | +0.84% | -60% |
| S&P | +12.65% | +91.73% | +13.89% | +243% |
Ardelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.
The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $110.33M | 12.3% |
| Gross Profit | $105.44M | 28.6% |
| Gross Margin | 95.57% | 12.1% |
| Market Cap | $1.33B | -18.1% |
| Market Cap / Employee | $3.36M | 0.0% |
| Employees | 395 | 47.9% |
| Net Income | -$0.97M | -19.8% |
| EBITDA | $5.57M | 100.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $42.72M | -9.9% |
| Accounts Receivable | $76.61M | 44.0% |
| Inventory | 25.2 | 121.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $206.18M | 102.3% |
| Short Term Debt | $1.44M | -44.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.24% | 8.8% |
| Return On Invested Capital | -65.24% | 5.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.21M | -42.6% |
| Operating Free Cash Flow | $0.37M | -27.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.59 | 6.74 | 6.44 | 9.51 | -7.79% |
| Price to Sales | 3.71 | 3.24 | 2.44 | 3.35 | -48.14% |
| Price to Tangible Book Value | 7.59 | 6.74 | 6.44 | 9.51 | -7.79% |
| Enterprise Value to EBITDA | 132.02 | -31.13 | -66.02 | 232.88 | -57.99% |
| Return on Equity | -23.0% | -36.3% | -39.4% | -36.2% | -12.90% |
| Total Debt | $153.44M | $155.11M | $206.64M | $207.61M | 98.69% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
